Angiotensin II-forming systems in cardiovascular diseases

Heart Failure Reviews

Volumn 3, Issue 2, 1998, Pages 119-124

  Urata, Hidenori ^a   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme; Cardiovascular disease; Cathepsin G; Chymase; Kallikrein

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CATHEPSIN G; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIKREIN;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

EID: 0032428367     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009783929020     Document Type: Article

References (51)

1. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JFM, Apstein CS, Lorell BH. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993;87:1328-1339.
2. Hokimoto S, Yasue H, Fujimoto K, Sakata R, Miyamoto E. Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction. Circ Res 1995;29:664-669.
3. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clincal evidence. Circ Res 1991;68:905-921.
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984; 144:1947-1953.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316: 1429-1435.
7. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-972.
8. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987;9(Suppl III):III-42-III-48.
9. Rousseau MF, Kostam MA, Benedict CR, Donckier J, Melin J, Kinan D, Ahn S, Ketelslegers JM, Pouleur H, Galanti L. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-493.
10. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-752.
11. Arakawa K. Serine protease angiotensin II systems. J Hypertens 1996;14:S3-S7.
12. Arakawa K, Yuki M, Ikeda M. Chemical identity of tryptensin with angiotensin. Biochem J 1980;187:647-653.
13. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'Kinintensin enzyme system'. Nature 1980;288:705-706.
14. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J 1989;30:219-229.
15. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993;27:334-340.
16. Urabe Y, Ideish M, Sasaguri M, Ikeda M, Arakawa K. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol 1993;72:218-222.
17. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994;12:1177-1181.
18. Boucher R, Asselin J, Genest J. A new enzyme leading to the direct formation of angiotensin II. Circ Res 1974;34&35 (Suppl. I):I-203-I-212.
19. Ikeda M, Sasaguri M, Maruta H, Arakawa K. Formation of angiotensin II by tonin-inhibitor complex. Hypertension 1988;11:63-70.
20. Le Trong H, Parmelee DC, Walsh KA, Neurath H, Woodbury RG. Amino acids sequence of rat mast cell protease I (chymase). Biochemistry 1987;26:6988-6994.
21. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU. Identification of a human neutrophil angiotensin II-generating protease as cathepsin G. J Clin Invest 1982;69:25-30.
22. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res 1979;44:540-544.
23. Trachte GJ, Lefer AM. Inotropic and vasoactive effects of the naturally occurring angiotensins in isolated cat cardiac muscle and coronary arteries. Res Commun Chem Pathol Pharmacol 1979;25:419-427.
24. Cornish KG, Joyner WL, Gilmore JP. Evidence for the conversion of angiotensin I to angiotensin II by the coronary microcirculation. Blood Vessels 1979;16:241-246.
25. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984;2:277-284.
26. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a hightly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
27. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
28. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus MF, Graham RM, Husain A. Cloning of the gene and cDNA for human heart chymase. J Biol Chem 1991;266:17173-17179.
29. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
30. Chen S, Chang M, Chiang BM, Cheng K, Lin C. Electromechanical effects of angiotensin in human atrial tissues. J Mol Cell Cardiol 1991;23:483-493.
31. Husain A, Kinoshita A, Sung SS, Urata H, Bumpus FM. Human heart chymase. In Lindpaintner K, Ganten D (eds), The Cardiac Renin-Angiotensin System. New York: Futura, 1994:309-331.
32. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II forming pathways by species and organs in vitro. J Hypertension 1998;32:514-520.
33. Benfey PN, Yin FH, Leder P. Cloning of the mast cell protease, RMCP II. J Biol Chem 1987;262:5377-5384.
34. Remington SJ, Woodbury RG, Reynolds RA, Matthews BW, Neurath H. The structure of rat mast cell protease II at 1.9-Å • resolution. Biochemistry 1988;27:8097-8105.
35. Le Trong H, Newlands GFJ, Miller HRP, Charbonneau H, Neurath H, Woodbury RG. Amino acid seqeuence of a mouse mucosal mast cell protease. Biochemistry 1989;28:391-395.
36. Serafin WE, Sullivan TP, Conder GA, Ebrahimi A, Marcham Patrick, Johnson SS, Austen KF, Reynolds DS. Cloning of the cDNA and gene for mouse mast cell protease: demonstration of its late transcription in mast cell subclasses and analysis of its homology to subclass-specific neutral proteases of the mouse and rat. J Biol Chem 1991;266: 1934-1941.
37. Caughey GH, Raymond WW, Vanderslice P. Dog mast cell chymase: molecular cloning and characterization. Biochemistry 1990;29:5166-5171.
38. Caughey GH, Zerweck EH, Vanderslice P. Structure, chromosomal assignment, and reduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem 1991;266: 12956-12963.
39. Shiota N, Fukamizu A, Takai S, Okunishi H, Murakami K, Miyazaki M. Activation of angiotensin II-forrning chymase in the cardiomyopathic hamster heart. J Hypertens 1997;15: 431-440.
40. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997;412:86-90.
41. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci U S A 1987;84:364-367.
42. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996;58: 591-597.
43. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise of plasma aldosterone during long-term captopril treatment (letter). N Engl J Med 1981;304:1110.
44. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45.
45. Hirakata H, Fouad-Tarazi FM, Bumpus FM, Khosla M, Healy B, Husain A, Urata H, Kumagai H. Angiotensins and the failing heart: enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circ Res 1990;66:891-899.
46. Shiota N, Fukamizu A, Takai S, Okunishi H, Murakami K, Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens 1997; 15:431-440.
47. Ihara M, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Local angiotensin II production and human artery diseases. J Hypertens 1996;14 (Suppl 1):S136.
48. Matsuo K, Kumagai K, Annoura M, Yamanouchi Y, Handa K, Nakashima Y, Hiroki T, Arakawa K. Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Pacing Clin Electrophysiol 1997;20:938-945.
49. Arakawa K, Okuda M, Maruta H, Ikeda M. A new bradykinin analogue lacking one proline residue formed from plasma protein by trypsin. Agents Action 1982;9 (Suppl):239-244.
50. Sasaguri M, Maeda H, Noda K, Tsuji E, Kinoshita A, Ideishi M, Ogata S, Arakawa K. Purification and characterization of a kinin- and angiotensin II- forming enzyme in the dog heart. J Hypertens 1997;15:675-682.
51. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997;159:1987-1992.